Verve Therapeutics, Inc. (VERV) Investors Suffered Losses; Contact Levi & Korsinsky
News Highlights
Levi & Korsinsky notifies investors in Verve Therapeutics, Inc. (NASDAQ: VERV) of a class action lawsuit and upcoming deadline.
Join the Lawsuit
To join the Verve Therapeutics class action lawsuit, contact us today:
- Phone: (844) 604-6444
- Email: support@zlk.com
- Visit: Levi & Korsinsky
About the Verve Therapeutics, Inc. Class Action Lawsuit
On July 26, 2023, a lawsuit was filed against Verve Therapeutics, Inc. alleging the company engaged in securities fraud.
The lawsuit alleges that the company made false and/or misleading statements by failing to disclose that Verve's lead gene editing therapy candidate, VERVE-101, had caused serious adverse events in nonhuman primates, including liver damage and immune system dysfunction, and that these adverse events were reasonably likely to occur in humans.
On July 28, 2023, Verve announced that the FDA had placed a clinical hold on the company's Phase 2a trial of VERVE-101 due to the serious adverse events observed in nonhuman primates.
As a result of the FDA clinical hold and the negative impact on the company's stock price, investors have suffered significant losses.
The class action lawsuit seeks to recover damages for Verve Therapeutics investors who purchased or acquired the company's securities between April 26, 2023 and July 28, 2023.
Who is Eligible?
Anyone who purchased or acquired Verve Therapeutics, Inc. (VERV) shares between April 26, 2023 and July 28, 2023 is eligible to participate in the Verve Therapeutics class action lawsuit.
Deadline
The deadline to file for lead plaintiff in the Verve Therapeutics class action lawsuit is September 26, 2023.
Comments